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Abstract
Background: Artemisinin-based combination therapies (ACTs) are the mainstay for the management of uncomplicated
malaria cases. However, up-to-date data able to assist sub-Saharan African countries formulating appropriate antimalarial
drug policies are scarce.
Methods and Findings: Between 9 July 2007 and 19 June 2009, a randomized, non-inferiority (10% difference threshold in
efficacy at day 28) clinical trial was carried out at 12 sites in seven sub-Saharan African countries. Each site compared three
of four ACTs, namely amodiaquine-artesunate (ASAQ), dihydroartemisinin-piperaquine (DHAPQ), artemether-lumefantrine
(AL), or chlorproguanil-dapsone-artesunate (CD+A). Overall, 4,116 children 6–59 mo old with uncomplicated Plasmodium
falciparum malaria were treated (1,226 with AL, 1,002 with ASAQ, 413 with CD+A, and 1,475 with DHAPQ), actively followed
up until day 28, and then passively followed up for the next 6 mo. At day 28, for the PCR-adjusted efficacy, non-inferiority
was established for three pair-wise comparisons: DHAPQ (97.3%) versus AL (95.5%) (odds ratio [OR]: 0.59, 95% CI: 0.37–0.94);
DHAPQ (97.6%) versus ASAQ (96.8%) (OR: 0.74, 95% CI: 0.41–1.34), and ASAQ (97.1%) versus AL (94.4%) (OR: 0.50, 95% CI:
0.28–0.92). For the PCR-unadjusted efficacy, AL was significantly less efficacious than DHAPQ (72.7% versus 89.5%) (OR: 0.27,
95% CI: 0.21–0.34) and ASAQ (66.2% versus 80.4%) (OR: 0.40, 95% CI: 0.30–0.53), while DHAPQ (92.2%) had higher efficacy
than ASAQ (80.8%) but non-inferiority could not be excluded (OR: 0.35, 95% CI: 0.26–0.48). CD+A was significantly less
efficacious than the other three treatments. Day 63 results were similar to those observed at day 28.
Conclusions: This large head-to-head comparison of most currently available ACTs in sub-Saharan Africa showed that AL,
ASAQ, and DHAPQ had excellent efficacy, up to day 63 post-treatment. The risk of recurrent infections was significantly
lower for DHAPQ, followed by ASAQ and then AL, supporting the recent recommendation of considering DHAPQ as a valid
option for the treatment of uncomplicated P. falciparum malaria.
Trial Registration: ClinicalTrials.gov NCT00393679; Pan African Clinical Trials Registry PACTR2009010000911750
Please see later in the article for the Editors’ Summary.
Citation: The Four Artemisinin-Based Combinations (4ABC) Study Group (2011) A Head-to-Head Comparison of Four Artemisinin-Based Combinations for
Treating Uncomplicated Malaria in African Children: A Randomized Trial. PLoS Med 8(11): e1001119. doi:10.1371/journal.pmed.1001119
Academic Editor: James G. Beeson, Walter and Eliza Hall Institute of Medical Research, Australia
Received March 16, 2011; Accepted September 30, 2011; Published November 8, 2011
Copyright:  2011 4ABC Study Group. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This project was funded by a grant of the European Developing Countries Clinical Trials Partnership (EDCTP). The Medicine for Malaria Venture (MMV)
provided additional funding mainly used for the genotyping of blood samples. The Belgian Directorate-General for Development Cooperation (DGDC) provided
support through the framework agreement programme between DGCD and the Institute of Tropical Medicine, Antwerp, Belgium. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Prof. Umberto d’Alessandro has received research funding from Sigma Tau and Sanofi-Aventis. Dr. Quique Bassat has received in the past
three years speaker fees and travel grants from Sigma Tau SP, Pomezia, Rome, Italy. All other authors declare no competing interests.
Abbreviations: ACPR, adequate clinical and parasitological response; ACT, artemisinin-based combination therapy; AE, adverse event; AL, artemether-
lumefantrine; ASAQ, amodiaquine-artesunate; CD+A, chlorproguanil-dapsone-artesunate; CI, confidence interval; DHAPQ, dihydroartemisinin-piperaquine; Hb,
hemoglobin; OR, odds ratio; ITT, intention to treat; SAE, serious adverse event; WHO, World Health Organization.
* E-mail: udalessandro@itg.be
" Membership of the Four Artemisinin-Based Combinations (4ABC) Study Group is provided in the Acknowledgments.
PLoS Medicine | www.plosmedicine.org 1 November 2011 | Volume 8 | Issue 11 | e1001119Introduction
The burden of malaria has declined substantiallyin several areas of
sub-Saharan Africa, particularly in the past 3–5 y [1]. Such a change
has been attributed to a combination of factors [2], including large
scale indoor residual spraying campaigns [3,4], massive distribution
of insecticide-treated bed nets [5], and the introduction of
artemisinin-based combination treatments (ACTs) [6,7]. The scale-
up of the interventions has been possible thanks to the availability of
more funding, especially from the Global Fund to Fight AIDS,
Tuberculosis and Malaria [8], that has allowed an increasing number
of countries to include ACTs in their national treatment guidelines as
first and, in some cases, second-line treatments, and to the massive
scale-up implementation of treatment programs [9]. In addition,
increased funding for research, often through effective public–private
partnerships [10], has resulted in the availability of several ACTs
[11]. However, data to guide individual countries in choosing the
mostappropriate ACTsare limited. The World Health Organization
(WHO),whichrecently produced revised guidelinesforthetreatment
of malaria, states that the choice of ACT in a country or region
should be based on the level of resistance to the medicine partnered to
the artemisinin derivative in the combination [12]. However, up-to-
date treatment efficacy data for the partner medicine to the
artemisinin derivative are scarce.
The WHO recommends five ACTs, namely artemether-lumefan-
trine (AL), amodiaquine-artesunate (ASAQ), mefloquine-artesunate,
sulfadoxine-pyrimethamine-artesunate, and, most recently included,
dihydroartemisinin-piperaquine (DHAPQ) [12]. Each of these
combinations may have different advantages and disadvantages that
vary according to a number of factors, including malaria endemicity,
safety, tolerability, dosing, post-treatment prophylactic effect, resis-
tance to the partner drug of the prevailing parasites in the area, and
price. Accordingly, we carried out a head-to-head comparison of the
safety and efficacy of several ACTs, with the aim of providing the
information necessary to make an informed choice for the
formulation of relevant national antimalarial treatment policies.
The ACTs tested included three of those recommended by the
WHO, namely AL, ASAQ, DHAPQ, and one that was under
development, chlorproguanil-dapsone-artesunate (CD+A).
AL was the first co-formulated ACT to become available and,
together with ASAQ, is the most common ACT used in sub-Saharan
Africa. DHAPQ has been recently submitted for registration to the
European Medicines Agency under the orphan drug legislation [13]
following two phase III trials that were carried out in Africa [14] and
Asia [15]. DHAPQ is currently used as a recommended treatment
only in Asia [16], and a formulation approved by a stringent drug
regulatory authority, such as the European Medicine Agency, or pre-
qualified by the WHO is not yet available. At the time our trial
started, combining chlorproguanil-dapsone (Lapdap, GlaxoSmith-
Kline) with artesunate (CD+A) was considered to be a promising
combination. Lapdap was on the market until 2008, when the
producer withdrew it following the results of several studies showing
that it caused significant reductions in hemoglobin (Hb) levels in
patients with glucose-6-phosphate dehydrogenase deficiency [17].
Therefore, the CD+A arm was stopped (because the drug was no
longer in development owing to concerns over safety), and our trial
continued with the other three ACTs under evaluation.
Methods
Study Design, Sites, and Concealment of Patient
Allocation
Between 9 July 2007 and 19 June 2009, a randomized, open-
label, multicenter, non-inferiority clinical trial was carried out at
12 sites located in seven African countries (Nanoro, Burkina Faso;
Fougamou and Lambare ´ne ´, Gabon; Afokang and Pamol, Nigeria;
Mashesha and Rukara, Rwanda; Jinja, Tororo, and Mbarara,
Uganda; Ndola, Zambia; and Manhic ¸a, Mozambique). See
protocol (Text S1) and amendments (Texts S3–S5), and
CONSORT checklist (Text S2).
Each site compared three of the four ACTs under investigation,
ASAQ, DHAPQ, AL, or CD+A. The decision of which treatments
to test at a given site was made by considering the current first-line
treatments, the known antimalarial resistance profile, and local
malaria endemicity (Table 1). Patients were individually random-
ized according to a 1:1:1 scheme, with six sites testing ASAQ
versus DHAPQ versus AL, four testing DHAPQ versus CD+A
versus AL, and two testing ASAQ versus CD+A versus DHAPQ
(Table 1). A randomization list was produced for each recruiting
site by the National Institute for Health Research Medicines for
Children Research Network Clinical Trials Unit, University of
Liverpool, UK, with each treatment allocation concealed in
opaque sealed envelopes that were opened only after the patient’s
recruitment.
Children 6–59 mo old (12–59 mo old at sites where CD+A was
used) attending the health facilities with suspected uncomplicated
malaria were included in the study if they fulfilled all the following
inclusion criteria: body weight .5 kg, microscopically confirmed
Plasmodium falciparum mono-infection with asexual parasite densities
between 2,000 and 200,000/ml, fever (axillary temperature
$37.5uC) or history of fever in the preceding 24 h, and Hb
$7.0 g/dl. Patients were not recruited if they met at least one of
the following exclusion criteria: participation in any other
investigational drug study during the previous 30 d; known
hypersensitivity to the study drugs; severe malaria [18] or other
danger signs, e.g., not able to drink or breast-feed, vomiting (more
than twice in 24 h), recent history of convulsions (more than once
in 24 h), unconscious state, or unable to sit or stand; severe
malnutrition (weight for height ,70% of the median National
Center for Health Statistics/WHO reference) or any other
concomitant illness or underlying disease, including known
glucose-6-phosphate dehydrogenase deficiency; contra-indication
to receive the trial drugs; or ongoing prophylaxis with drugs
having antimalarial activity. Patients satisfying these eligibility
criteria were enrolled if the parent/guardian gave informed
consent to participate and signed the corresponding form.
Three treatments were co-formulated (ASAQ, DHAPQ, and
AL), while CD+A consisted of separate tablets of chlorproguanil-
dapsone and artesunate. All drugs were administered under direct
supervision during three consecutive days, according to the
patient’s body weight. ASAQ (Coarsucam, Sanofi Aventis) was
given once daily, at the standard dose of 2.8–5.5 mg/kg and 7.5–
15 mg/kg of artesunate and amodiaquine, respectively. Three
formulations were used (25 mg artesunate +67.5 mg amodiaquine;
50 mg artesunate +135 mg amodiaquine; and 100 mg artesunate
+270 mg amodiaquine) and given at the dosage of one tablet/day
according to body weight (,9 kg, 9–17.9 kg, and 18–35.9 kg,
respectively). DHAPQ (Eurartesim, Sigma-Tau) was given once
daily, at the standard dosage of 2.25 mg/kg and 18 mg/kg of
dihydroartemisinin and piperaquine, respectively, rounded up to
the nearest half tablet. Two formulations were used (20 mg
dihydroartemisinin +160 mg piperaquine and 40 mg dihydroar-
temisinin +320 mg piperaquine). AL (Coartem, Novartis) was
administered twice a day (at enrollment and at 8, 24, 36, 48, and
60 h) according to the following dosage: weight=5–14 kg: one
tablet per dose; weight=15–24 kg: two tablets per dose;
weight=25–34 kg: three tablets per dose. Chlorproguanil-dap-
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tered once a day at the dose of 2.0 mg/kg chlorproguanil and
2.5 mg/kg dapsone. The daily dose of the formulation used
(15 mg chlorproguanil and 18.75 mg dapsone) was given accord-
ing to body weight, i.e., 4–5.9 kg: 0.5 tablet; 6–9.9 kg: 1 tablet;
10–13.9 kg: 1.5 tablet; 14–15.9 kg: 2 tablets; 16–19.9 kg: 2.5
tablets; 20–24.9 kg: 3 tablets; 25–30.9 kg: 4 tablets. Arsumax
(Guilin Pharmaceutical for Sanofi-Synthelabo) contained 50 mg
artesunate per tablet and was administered with chlorproguanil-
dapsone according to the following dosage: 5–8.3 kg: 0.5 tablet;
8.4–16.7 kg: 1 tablet; 16.8–20.8 kg: 1.5 tablet; 20.9–29.2 kg: 2
tablets. In case of vomiting, a full dose was repeated if this
occurred within 30 min, or half a dose if it occurred between
30 min and 1 h. AL was administered concomitantly with a fatty
meal (as recommended by the manufacturer), e.g., milk or
groundnuts, while for the other three treatments no specific
instructions regarding co-administration with food were given. For
infants, medicines were crushed, mixed with water, and admin-
istered as a slurry. Treatment was administered by a study nurse,
with the clinician or other staff following up the patient and
assessing the end points blinded to the treatment assignment
whenever possible.
Treatment Follow-Up and Clinical and Laboratory
Procedures
Treatment was directly observed and children stayed at the
health facility at least 1 h to check for any vomiting. At some sites
children were kept at the health facility for the whole 3-d dosing
period. The parent/guardian was asked to return with the child for
scheduled visits on days 3, 7, 14, 21, and 28, or if any symptoms
occurred (active follow-up period). Field workers traced patients
whomissedanyvisit.Inaddition,afterday28and forthenext6mo,
the parent/guardian was encouraged to attend the health facility
whenever the child was sick, so as to detect any malaria episode(s)
(passive follow-up period). In case of clinical malaria, the child
received the same treatment as for the primary episode and was
actively followed up for the following 28 d (unpublished data). For
each visit, a physical examination was performed by the study
clinicians, vital signs were recorded, and axillary temperature was
measured with an electronic thermometer. Adverse events (AEs)
and serious adverse events (SAEs) were recorded and monitored
throughout the study. Rescue treatment for recurrent infections
identified during the 28-d follow-up, as well as for severe malaria,
was according to local national guidelines.
Capillary or venous blood was taken at every visit. Thick and
thin blood films were prepared, dried, and Giemsa-stained, and
parasite density estimated by counting the number of asexual
parasites in 200 white blood cells, assuming a standard white blood
cell count of 8,000/ml. Quality control was performed in blind
conditions on 10% of all the slides. Samples for hematology (full
blood count) were taken at enrollment and at days 3, 7, 14, and 28,
while biochemistry (liver and renal functions) was performed at
enrollment and days 7 and 28. Laboratory tests were also
performed at any other visit if judged necessary by the clinician.
For PCR analysis, blood samples were collected on filter paper
(Whatman 3MM) at enrollment and at any visit after day 7. Each
filter paper was dried and individually stored in a plastic bag
containing silica gel. All filter papers were subsequently transport-
ed to the Institute of Tropical Medicine, Antwerp, Belgium, where
centralized genotyping according to international recommenda-
tions was conducted [19]. Briefly, purification of DNA was
conducted as previously described [20] and three polymorphic
genetic markers were genotyped sequentially, starting with GluRP,
followed by MSP2, and ending with MSP1. Capillary electropho-
resis was used for MSP2. Whenever a genetic marker showed a
new infection, i.e., no common allele between day of recurrent
infection and day 0, this was taken as the final result and the
analysis was stopped. For samples showing a recurrent infection,
i.e., at least one identical allele between day 0 and day of recurrent
infection, the analysis was carried out until MSP1. If the latter
showed also at least one identical allele between day of recurrent
infection and day 0, then the infection was classified as a
recrudescence [19]. All results were double read and discrepancies
resolved.
Outcome Classification
Treatment outcomes were classified according to the WHO
guidelines [21], as early treatment failure, late clinical failure, late
parasitological failure, and adequate clinical and parasitological
response (ACPR). An AE was defined as any untoward medical
occurrence, irrespective of its suspected relationship to the study
medication, in accordance with the International Conference of
Harmonization guidelines, and graded as mild, moderate, severe,
or life-threatening.
Table 1. Study treatment to be tested by country.
Country Sites
Transmission (Entomological
Inoculation Rate)
Percent with Chloroquine
Resistance
Percent with Sulfadoxine-
Pyrimethamine Resistance Study Treatments
Burkina Faso Nanoro Seasonal, high (50–60)[46] 24 [46] 4 [46] ASAQ DHAPQ AL
Gabon Fougamou,
Lambare ´ne ´
Perennial, high (50) 100 [47] 23 [48] ASAQ DHAPQ AL
Nigeria Afokang, Pamol Perennial, high 45 [49] 30 [49] ASAQ DHAPQ AL
Zambia Ndola Seasonal, mesoendemic High 19 (in adults) [50] ASAQ DHAPQ AL
Rwanda Rukara Seasonal, high 40 [51] 36 [51] DHAPQ CD+AA L
Rwanda Mashesha Seasonal, high 50 [51] 12 [51] DHAPQ CD+AA L
Uganda Jinja Perennial, low (6) [34] 28 [52,53] 49 [52,53] DHAPQ CD+AA L
Uganda Tororo Perennial (.563) [34] 45 [52,53] 9–15 [52,53] DHAPQ CD+AA L
Mozambique Manhic ¸a Perennial, mesoendemic [54] 78 [55] 22 [55] ASAQ CD+A DHAPQ
Uganda Mbarara Mesoendemic 81 [56] 25 [56] ASAQ CD+A DHAPQ
Entomological inoculation rate is infective bites/person/year.
doi:10.1371/journal.pmed.1001119.t001
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ACPR at day 28; secondary efficacy outcomes included PCR-
adjusted and unadjusted ACPR at day 63 (day 28 plus days 29–63,
the latter with passive detection of clinical malaria cases) [22],
parasite and fever clearance times, presence and clearance of
gametocytes, Hb changes from baseline to days 3, 7, 14, and 28,
and safety profiles. All standard safety outcomes, such as incidence
of AEs, changes from baseline on hematology and clinical
chemistry parameters, and vital sign variations during the study
were evaluated. PCR-unadjusted ACPR included as treatment
successes only patients classified as ACPR at the end of the follow-
up period while PCR-adjusted ACPR also included as successes
patients classified as either late clinical failure or late parasitolog-
ical failure for whom the recurrent infection was identified by
genotyping as a new infection. An independent end point
adjudication committee comprising three individuals (not authors
or investigators in the trial) blind to both treatment allocation and
PCR results reviewed records with discrepancies between the
outcome registered by the investigators and the information
collected during follow-up and assigned a final outcome. The end
point adjudication committee also reviewed the patients lost to
follow-up or withdrawn, to determine any possible relation with
the study drug or malaria.
Ethical Considerations and Patient Safety
The study protocol and successive amendments were approved
by the Institutional Review Board of the Institute of Tropical
Medicine, Antwerp; the Ethical Committee of the Antwerp
University Hospital; the national Ethics Review Committee or
Institutional Review Board at each trial site; and the national
competent authorities, as appropriate, e.g., Ministry of Health and
national drug regulatory authorities. The trial was conducted
under the provisions of the Declaration of Helsinki and in
accordance with Good Clinical Practices guidelines set up by the
WHO and by the International Conference on Harmonization.
An independent Data Safety and Monitoring Committee was
created prior to the beginning of the trial and regularly reviewed
both the safety data and the quality of the information collected.
The trial was registered prior to the enrollment of the first patient
in the ClinicalTrials.gov registry (NCT00393679, http://clinical-
trial.gov/ct2/show/NCT00393679) and in the Pan African
Clinical Trials Registry (/PACTR2009010000911750, http://
www.pactr.org/).
Statistical Analysis
A Statistical Analysis Plan was finalized before data extraction,
and statistical analysis was performed accordingly. For the primary
outcome, four analysis approaches were adopted: intention to treat
(ITT), per protocol, and two sensitivity analyses. Patients lost to
follow-up or withdrawn for reasons unrelated to malaria, as
determined by the end point adjudication committee, were
excluded from the ITT analysis. Major protocol violators defined
prior to analysis (no blood slide or parasite density .200,000/mla t
day 0, no fever or history of fever and parasite density ,2,000/ml,
Hb at day 0,7.0 g/dl, signed informed consent not available, any
of the exclusion criteria at day 0 except known hypersensitivity to
the study drug, study drug either not taken or ,80% of the dose
taken, administration of a treatment with antimalarial activity
during the follow-up) were excluded from the per protocol
analysis. All secondary outcomes were analyzed using the ITT
approach, with patients having received rescue treatment or lost to
follow-up censored at their last visit. Because CD+A was
discontinued partway through the study and the lower age limit
for inclusion changed at that time, the analyses involving CD+A
include only patients randomized prior the discontinuation.
The primary hypothesis was that the four treatments are
clinically non-inferior to each other as measured by the proportion
of children with PCR-adjusted and unadjusted ACPR at day 28.
This was tested for each of all possible (six) pair-wise comparisons
and the two primary end points, with the limit of non-inferiority
on an odds ratio (OR) scale corresponding to a 10% absolute
difference in ACPR. Data from sites testing the same two
treatments were included and combined into a meta-analysis
using the study site as unit.
The meta-analysis was performed using ORs rather than risk
differences as the latter usually display more heterogeneity than ORs
[23]. Nevertheless, for each site, we also report the risk differences
and 95% confidence intervals (CIs) calculated using Wilson’s score
method, together with the non-inferiority limit [24]. Heterogeneity
was examined by visually inspecting the OR and the 95% CI in a
forest plot. Additionally, qualitative heterogeneity was declared if
there was at least one site with a statistically significant treatment
difference in one direction (CI for measure of effect entirely above
point of no difference) and at least one site with a difference in the
opposite direction (CI for measure of effect entirely below point of no
difference). For this assessment, a clinical significance level of 10%
(i.e., 90% CIs in the forest plot) was used. For each pair-wise
comparison, provided no qualitative heterogeneity was present, the
pooled OR and corresponding 95% CI were computed, with the
treatment having the highest ACPR taken as control.
For the secondary outcomes, including ACPR at day 63,
differences between treatments were estimated using differences in
means, ORs, or hazard-ratios, as appropriate, and the corresponding
95% CIs. Parasite and fever clearance were defined as two
consecutive days without parasite or fever, respectively, and analyzed
using Cox proportional hazard models stratified by study site.
Gametocyte prevalences were assessed by calculating the number of
gametocyte carriage days for each patient as an area under the curve.
The number of gametocyte carriage days was analyzed using zero-
inflatedPoissonmodelswiththenumberofdaysinactivefollow-upas
offset, and summarized as ORs (for zero gametocyte carriage days)
and ratios of the expected number of gametocyte carriage days
between groups. This last ratio is expressed as the percentage of the
reduction in gametocyte carriage days.
Safety was assessed through AE reporting; all individuals having
received at least one dose of the treatment were included and
analyzed according to the treatment actually received.
Sample Size Calculation
This study was designed as a non-inferiority trial, and on an
expected ACPR at day 28 of at least 90%. Though the primary
intention was to carry out a pooled analysis able to provide overall
head-to-head comparisons between the different treatments, the
sample size was based on the individual sites to also produce
locally meaningful results. Therefore, for each individual site, 170
children per arm should be able to show that the difference in
efficacy between treatments was less than 10%, at 5% significance
level and 90% power, assuming equal true ACPR rates.
Results
Trial Profile and Baseline Characteristics
Overall, 11,030 patients were screened, 6,382 did not meet the
inclusion/exclusion criteria, 532 declined to participate, and 4,116
were recruited and randomized to receive the study drugs (1,226
to AL, 1,002 to ASAQ, 413 to CD+A, and 1,475 to DHAPQ)
(Figure 1). The smaller sample size in the CD+A group is
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development [17] and the subsequent closure of this treatment arm
in February 2008. Therefore, at sites where CD+A was one of the
study treatments, patients enrolled after 17 February 2008 were
randomized to the remaining two study drugs and the lower age
limit was changed from 12 to 6 mo. For the ITT analysis of the
PCR-unadjusted ACPR at day 28, 3,874 patients were included,
while 105 (2.6%) (35 for ASAQ, 37 for DHAPQ, 29 for AL, and 4
CD+A,) were lost to follow-up and 137 (3.3%) (38 for ASAQ, 57 for
DHAPQ, 26 for AL, and 16 for CD+A) were withdrawn for reasons
definitely or probably not related to malaria or treatment. In
addition, for the PCR-adjusted ACPR (ITT population), 71
additional patients were excluded because of either indeterminate
PCR results or unavailable blood sample (20 for ASAQ, 12 for
DHAPQ, 25 for AL, and 14 for CD+A). Randomization generated
comparable groups within countries and overall (Table 2).
The safety analysis included all other randomized patients apart
from eight patients: two (randomized to DHAPQ) were withdrawn
before receiving the study drug (one because of violation of entry
criteria, one withdrawal of consent) and six were withdrawn
because they vomited their first dose twice (four for DHAPQ, one
for AL, and one for CD+A).
Efficacy Results
All results presented below refer to the ITT analysis unless
specified otherwise. As an indication of the overall efficacy of the
different treatments, the pooled results are reported below.
However, the analysis of each of the six pair-wise comparisons
was stratified by site. The pooled (all sites) PCR-adjusted ACPR
was high, around 95%, for ASAQ, DHAPQ, and AL, both at day
28 and 63, while for CD+A this was around 85%. In addition,
CD+A had the lowest PCR-unadjusted ACPR, followed by AL,
ASAQ, and then DHAPQ, with the majority of recurrences due to
new infections (Table 3). At day 63, DHAPQ and ASAQ had
similar PCR-unadjusted ACPR, though for the latter, recurrent
infections occurred earlier (Figure 2). None of the pair-wise
comparisons showed important qualitative heterogeneity. For the
PCR-adjusted ACPR at day 28, non-inferiority could be
established for the following pair-wise comparisons: AL versus
DHAPQ (95.5% [1,094/1,146] versus 97.3% [1,019/1,047]; OR:
0.59, 95% CI: 0.37–0.94), ASAQ versus DHAPQ (96.8% [880/
909] versus 97.6% [785/804]; OR: 0.74, 95% CI: 0.41–1.34), and
AL versus ASAQ (94.4% [559/592] versus 97.1% [568/585];
OR: 0.50, 95% CI: 0.28–0.92). CD+A had a significantly lower
efficacy than the other ACTs, but non-inferiority could not be
ruled out (Figure 3). For the day 28 PCR-unadjusted ACPR, none
of the pair-wise comparisons could establish the predefined non-
inferiority (Figure 3). AL was significantly less efficacious than
DHAPQ (72.7% [851/1171] versus 89.5% [943/1054]; OR: 0.27,
95% CI: 0.21–0.34) and ASAQ (66.2% [400/604] versus 80.4%
[480/597]; OR: 0.40, 95% CI: 0.30–0.53), while in the
comparison between ASAQ and DHAPQ, the latter had a higher
Figure 1. Trial profile up to day 28. Adj TF, adjusted treatment failure; Unadj TF, unadjusted treatment failure.
doi:10.1371/journal.pmed.1001119.g001
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929] versus 92.3% [750/813]; OR: 0.35, 95% CI: 0.26–0.48)
(Figure 3). DHAPQ, ASAQ, and AL were significantly more
efficacious than CD+A, with the 95% CI well below the limit of
non-inferiority (Figure 3). The analyses in the per protocol
population and all sensitivity analyses confirmed the robustness
of these results (data not shown).
Day 63 results were similar to those observed at day 28. For the
PCR-corrected efficacy, DHAPQ, ASAQ, and AL had high
($94.6%) and similar efficacy. CD+A, in each pair-wise
comparison, had a significantly lower efficacy (,85%) than any
of the other three treatments. PCR-unadjusted efficacy was
significantly higher for DHAPQ than for ASAQ (73.6% [598/
813] versus 67.7% [629/929]; OR: 0.77, 95% CI: 0.61–0.96) and
AL (65.5% [690/1054] versus 57.8% [677/1171]; OR: 0.64, 95%
CI: 0.52–0.79), while that for ASAQ was significantly higher than
for AL (65.8% [393/597] versus 57.5% [347/604]; OR: 0.62,
95% CI: 0.47–0.81). CD+A had a significantly lower efficacy than
the other three treatments (Figure 3). Pair-wise comparisons of
ACPR by site, both PCR-adjusted and unadjusted, followed a
Table 2. Baseline characteristics (ITT population).
Variable Treatment Group
ASAQ (n=1,002) DHAPQ (n=1,475) AL (n=1,226) CD+A( n=413)
Male/female: number (percent) 558/444 (55.7/44.3) 780/695 (52.9/47.1) 627/559 (51.1/48.9) 214/199 (51.8/48.2)
Age (mo), mean (SD) 30.2 (14.7) 30.2 (14.1) 29.5 (14.0) 30.7 (12.8)
Weight (kg), mean (SD) 11.4 (3.0) 11.4 (2.8) 11.1 (2.8) 11.6 (2.6)
Fever, n (percent) 611 (61.0) 918 (62.2) 704 (57.4) 244 (59.1)
Temperature (u C), mean (SD) 38.0 (1.3) 38.0 (1.2) 37.8 (1.2) 37.9 (1.3)
Parasite density (10
3), median (IQR) 30 (10–65) 31 (10–68) 27 (10–58) 32 (12–65)
Presence of gametocytes, n (percent) 104 (10.4) 166 (11.3) 94 (7.7) 68 (16.5)
Hb (g/dl), mean (SD) 9.1 (1.4) 9.4 (1.5) 9.2 (1.5) 9.7 (1.4)
Leucocytes (10
9/l), mean (SD) 9.7 (3.9) 9.8 (3.8) 9.5 (3.9) 9.8 (3.8)
Splenomegaly, n (percent) 49 (4.9) 88 (6.0) 80 (6.5) 27 (6.5)
Hepatomegaly, n (percent) 6 (0.6) 5 (0.3) 8 (0.7) 1 (0.2)
ALAT (IU/l), median (IQR) 23 (16–33) 23 (17–33) 24 (16–33) 25 (19–36)
Bilirubin (mmol/l), median (IQR) 15 (10–24) 15 (9–24) 14 (9–21) 16 (8–27)
Creatinine (mmol/l), median (IQR) 38 (31–44) 44 (34–58) 45 (35–62) 40 (31–60)
ALAT, alanine aminotransferase; IQR, interquartile range; SD, standard deviation.
doi:10.1371/journal.pmed.1001119.t002
Table 3. Treatment outcomes by treatment.
Outcome Details ASAQ (n=1,002) DHAPQ (n=1,475) AL (n=1,226) CD+A( n=413)
Excluded from ITT analysis,
percent (n)
Withdrawal unrelated to study treatment or
malaria
3.8 (38) 3.9 (57) 2.1 (26) 3.9 (16)
Lost to follow-up 3.5 (35) 2.5 (37) 2.4 (29) 1.0 (4)
Day 28: no PCR results 2.0 (20) 0.8 (12) 2.0 (25) 3.4 (14)
Day 63: no PCR results 6.4 (64) 5.6 (83) 5.5 (67) 8.2 (34)
ACPR, percent (n/N) Day 28: PCR unadjusted 80.8 (751/929) 90.5 (1,250/1,381) 72.7 (851/1,171) 56.5 (222/393)
Day 28: PCR adjusted 96.8 (880/909) 97.6 (1,336/1,369) 95.5 (1,094/1,146) 86.0 (326/379)
Day 63: PCR unadjusted 67.7 (629/929) 68.8 (950/1,381) 57.8 (677/1,171) 40.5 (159/393)
Day 63: PCR adjusted 95.8 (829/865) 95.7 (1,242/1,298) 94.6 (1,044/1,104) 84.1 (302/359)
Treatment failures, n ETF 2 2 0 1
LTF (day 28): new infections 149 98 268 118
LTF (day 28): recrudescences 18 22 41 49
Deaths (up to day 63) 1 1 3 1
Withdrawal related to treatment or malaria 8 8 9 2
LTF (day 29–63): new infections 115 277 166 59
LTF (day 29–63): recrudescences 7 23 8 4
ITT population; results pooled from all sites.
ETF, early treatment failure; LTF, late treatment failure (includes late parasitological and clinical failures; after day 28, only late clinical failures were detected).
doi:10.1371/journal.pmed.1001119.t003
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sites, PCR-unadjusted efficacy of DHAPQ as compared to AL was
significantly higher in Ndola (Zambia), Tororo (Uganda), and
Nanoro (Burkina Faso), while at the other sites it was similar or the
difference did not reach statistical significance (Figure 4C); for the
comparison with ASAQ, DHAPQ performed significantly better
at most sites, with the exception of Pamol and Afokang (Nigeria)
(Figure 4A). In addition, the PCR-unadjusted efficacy of ASAQ
was significantly higher than that of AL in Nanoro (Burkina Faso),
while at the other sites the risk difference was close to zero
(Figure 4B).
DHAPQ had a PCR-adjusted efficacy similar to that of AL at
most sites, with the exception of Pamol (Nigeria), where AL
efficacy both at day 28 and 63 tended to be higher, and in Nanoro
(Burkina Faso), with a significantly higher efficacy of DHAPQ at
day 28 but not at day 63 (Figure 4C). PCR-adjusted efficacy for
DHAPQ and ASAQ was similar at most sites, with the exception
of Pamol (Nigeria), where ASAQ performed significantly better
than DHAPQ (Figure 4A). The PCR-adjusted efficacy of ASAQ
and AL were similar at most sites, with the exception of Nanoro
(Burkina Faso), where at day 28 ASAQ performed significantly
better than AL (Figure 4B).
Parasite clearance was rapid in all treatment groups as the large
majority of patients had no detectable infection at day 3, with no
major differences in the time of clearance between treatment
groups (Table 4). Similarly, about 60% of patients had fever at
baseline (Table 2), while at day 3 more than 95% of patients were
afebrile, with no major differences among treatment groups in
terms of fever clearance time (Table 4).
The evolution of gametocyte prevalence by treatment group is
shown in Figure 5. Gametocyte prevalence during follow-up was
significantly lower in patients treated with AL than in those treated
with DHAPQ (OR: 0.79, 95% CI: 0.64–0.99), ASAQ (OR: 0.72,
95% CI: 0.55–0.95), or CD+A (OR: 0.50, 95% CI: 0.31–0.82)
(Table 4). However, when excluding patients with gametocytes at
enrollment, AL had significantly lower gametocyte prevalence
only for the pair-wise comparison with CD+A (Table 4). The time
(in days) of gametocyte carriage was significantly shorter in the AL
group than in the ASAQ and DHAPQ groups, both when
including all patients and excluding those with gametocytes at
enrollment (Table 4).
Hb increased in all treatment groups and attained the day 0
levels at day 7, except in patients treated with CD+A (Figure 6). In
the three pair-wise analyses without CD+A, i.e., AL versus
DHAPQ, AL versus ASAQ, and ASAQ versus DHAPQ, no
important differences in Hb change were found. Conversely, in all
pair-wise analyses involving CD+A, Hb recovery was significantly
slower in the CD+A than in the other treatment group, with
significant differences at days 3 and 7 (Table 4).
Safety Results
A total of 4,108 patients were included in this analysis. Up to
day 28, 37 patients experienced SAEs, their occurrence being
relatively more frequent in patients treated with ASAQ or CD+A
than among those treated with DHAPQ or AL (Table 5). Most
SAEs judged by the site investigator to be related to the study
treatment occurred during the first week of follow-up, including
four anemia cases, two of them in the CD+A group. There were
five deaths, none of them considered related to treatment, a severe
malaria case in the ASAQ group, one death due to diarrheal
disease in the DHAPQ group, a sudden death in the CD+A group,
and two deaths in the AL group (severe malaria and unknown
cause) (Table 5). In addition, between days 28 and 63, a severe
malaria death occurred in the AL group.
Figure 2. Proportion of patients whose treatment was failure-free by day of follow-up. ITT population; data pooled over all sites.
doi:10.1371/journal.pmed.1001119.g002
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experienced at least one AE (Table 5). Vomiting occurred in about
10% of patients (ASAQ: 10.6%; DHAPQ: 8.4%; AL: 8.3%;
CD+A: 12.6%), while decreased Hb identified as an AE occurred
more frequently in the CD+A group (Table 5). Similarly, anemia
was diagnosed more frequently in the CD+A group, while the AL
group had the lowest occurrence (Table 5).
The median levels of alanine aminotransferase and creatinine
before treatment, as well as the proportion of patients with values
above the normal range (both clinically and non-clinically significant,
the latter not shown), were similar between the four study arms, and
this did not change during the follow-ups at day 7 and 28 (Table 6).
Discussion
This large multicenter trial aimed to collect information that
would assist national malaria control programs in sub-Saharan
African countries in choosing the most appropriate ACTs for their
specific setting. The four ACTs most likely to be considered for
this purpose at the time the study was conceived and implemented,
namely AL, ASAQ, DHAPQ, and CD+A, were compared at 12
sites distributed over seven countries. The development of CD+A
was discontinued partway through the study, following the results
of a phase III clinical trial that showed a higher risk for severe and
clinically concerning Hb decrease [25], while a new ACT,
pyronaridine-artesunate, is likely to become an additional ACT
to be considered [26].
Each site tested three of the four ACTs, i.e., in ten sites both AL
and DHAPQ were tested; in six of these the third arm was ASAQ
and in the other four, CD+A; two additional sites tested ASAQ,
DHAPQ, and CD+A. Following the discontinuation of the CD+A
arm, six sites continued testing only two study treatments. Such
study design does not allow the use of the pooled results of the four
study treatments, as the efficacy of a given ACT tested in one site
cannot be directly compared with that of another ACT tested only
in another site. Therefore, it is necessary to analyze the six pair-
wise comparisons and to include in each comparison only sites in
which the two study treatments were actually tested.
When considering the pooled data across all sites, non-
inferiority could be established for the three pair-wise comparisons
without CD+A, indicating that ASAQ, AL, and DHAPQ had
similar and high PCR-adjusted efficacy, both at day 28 and 63;
efficacy was lower for CD+A. Conversely, the unadjusted efficacy
estimates were higher for DHAPQ, followed by ASAQ and then
AL, though at day 63 the difference between DHAPQ and ASAQ
seemed to disappear; also in this case CD+A had a much lower
efficacy than the other three treatments. It is important to mention
that beyond day 28, the detection of recurrent infections was
passive, i.e., only sick children attending the health facility had a
blood slide prepared, so that some asymptomatic infections may
not have been detected. Nevertheless, the important difference in
the PCR-unadjusted efficacy between day 28 and 63 suggests that
during this period a substantial proportion of children had a
recurrent malaria infection, mostly a new infection, as indicated by
the small difference between the PCR-adjusted efficacy at day 28
and 63.
The site-specific estimates mirror the overall results, with some
notable and surprising exceptions. DHAPQ had the highest PCR-
Figure 3. Six pair-wise comparisons at day 28 and day 63. OR (circles), 95% CI (horizontal bars), and non-inferiority limit (vertical bars) for each
pair-wise analysis for PCR-unadjusted (left panel) and -adjusted (right panel) ACPR at days 28 (filled circles) and 63 (open circles) (ITT population). An
OR and 95% CI,1 indicate a significantly higher efficacy of the second versus the first treatment of the pair-wise comparison. The non-inferiority
limits (day 28 only) correspond to a 10% difference in efficacy, recalculated to an OR scale. Non-inferiority is established if the 95% CI lies completely
above the non-inferiority limit.
doi:10.1371/journal.pmed.1001119.g003
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transmission, e.g., Nanoro (Burkina Faso) and Tororo (Uganda), so
that the difference observed can be explained by the long post-
treatment prophylactic period related to the slow elimination of
piperaquine. This is also the reason why DHAPQ performed
better than ASAQ at the only high-transmission site where it was
tested, i.e., Nanoro (Burkina Faso). Nevertheless, it is surprising
that PCR-unadjusted efficacy for DHAPQ was significantly better
than that of AL and ASAQ in Ndola (Zambia), where transmission
has decreased dramatically over the past few years, to the extent
that the target sample size for this trial could not be attained.
Unlike Tororo (Uganda), where the PCR-adjusted efficacies for
AL and DHAPQ were similar, in Ndola (Zambia), such efficacy
tended to be higher for DHAPQ, and the difference probably did
not reach statistical significance because of the small sample size,
though AL efficacy was almost 95%. Similarly, at this site the
difference between DHAPQ and ASAQ PCR-adjusted efficacy
was of borderline significance, though ASAQ efficacy was about
94%. It is unclear what such differences mean, as all treatments,
with the exception of CD+A, had a PCR-adjusted efficacy .90%
and the trial aimed at showing non-inferiority at a 10% difference
threshold. Non-inferiority was demonstrated for the three pair-
wise comparisons involving DHAPQ, ASAQ, and AL at most
sites, with a few exceptions where the individual sites’ 95% CI
cross the non-inferiority limit.
In west Africa, ASAQ continues to have excellent efficacy,
comparable to that of AL [27,28], while in east Africa doubts
about its use have been expressed [29]. Indeed, in a study carried
out in Kampala, Uganda, ASAQ had a lower efficacy than AL, a
result confirmed in subsequent years [30]. The superior efficacy of
AL compared to ASAQ was explained by the presence of
amodiaquine resistance in east Africa that may render this ACT
increasingly less efficacious, similar to what has been observed for
sulfadoxine-pyrimetamine-artesunate in east Africa [29]. In
Tanzania, AL was significantly better than ASAQ, but this was
an effectiveness study, i.e., the treatment administration was not
supervised, and ASAQ was not co-formulated, two important
factors that may have influenced the treatment outcome [31]. In
our study, although ASAQ was tested mainly in west Africa, it also
had excellent efficacy at sites located in eastern and southern
Africa, namely Mbarara (Uganda), Ndola (Zambia), and Manhic ¸a
(Mozambique). However, the choice of the ACTs to test at the
individual sites was influenced by their known drug resistance
profile, i.e., ASAQ was not tested in sites with known high
amodiaquine resistance. Therefore, although ASAQ is a possible
option for some countries in east Africa, it should be not be
deployed where amodiaquine resistance is known to be high. For
the PCR-unadjusted efficacy at days 28 and 63, none of the pair-
wise comparisons could show non-inferiority. Instead, DHAPQ
was the best treatment, followed by ASAQ, AL, and then CD+A,
which was consistently inferior to the three other ACTs.
Considering that most of the recurrent infections were due to
new infections and that the risk of re-infection depends on the
activity of the non-artemisinin component, this result is largely
expected. Indeed, piperaquine has the longer elimination half-life
(about 23–28 d), followed by amodiaquine (3 wk), lumefantrine
Table 4. Secondary outcomes by pair-wise comparison.
Outcome
ASAQ versus
DHAPQ
AL versus
ASAQ
AL versus
DHAPQ
CD+A versus
ASAQ
CD+A versus
DHAPQ CD+A versus AL
Parasite clearance time (days)
a 1.00 (0.91, 1.10) 0.92 (0.82, 1.03) 0.91 (0.84, 0.99) 1.04 (0.84, 1.28) 1.03 (0.90, 1.19) 1.10 (1.02, 1.20)
Fever clearance time (days)
a 1.08 (0.99, 1.19) 0.88 (0.79, 0.99) 0.95 (0.87, 1.03) 0.95 (0.77, 1.17) 0.99 (0.87, 1.14) 1.10 (0.81, 1.32)
Gametocyte carriage: all
patients
b
OR (for excess of patients with
zero gametocytes)
0.88 (0.70, 1.11) 1.39 (1.05, 1.82) 1.26 (1.01, 1.57) 1.11 (0.63, 1.96) 0.81 (0.57, 1.14) 0.50 (0.31, 0.81)
Ratio of gametocyte carriage days 1.05 (0.97, 1.14) 0.59 (0.52, 0.66) 0.68 (0.62, 0.76) 0.82 (0.66, 1.02) 0.89 (0.76, 1.04) 0.95 (0.75, 1.20)
Gametocyte carriage: patients
without gametocytes at
enrollment
b
OR (for excess of patients
with zero gametocytes)
0.75 (0.56, 1.00) 1.29 (0.93, 1.79) 1.02 (0.77, 1.36) 0.94 (0.38, 2.29) 0.74 (0.44, 1.27) 0.38 (0.18, 0.82)
Ratio of gametocyte carriage days 1.16 (1.00, 1.33) 0.53 (0.44, 0.63) 0.63 (0.53, 0.74) 0.44 (0.31, 0.87) 1.08 (0.76, 1.54) 1.19 (0.72, 1.96)
Change Hb (g/dl) day 0–day 3
c 20.04 (20.13, 0.05) 0.05 (20.06, 0.16) 0.02 (20.06, 0.10) 20.24 (20.47, 20.01) 20.38 (20.51, 20.25) 20.26 (20.43, 20.08)
Change Hb (g/dl) day 0–day 7
c 20.05 (20.16, 0.05) 0.07 (20.06, 0.21) 0.11 (0.01, 0.20) 20.41 (20.67, 20.15) 20.48 (20.64, 20.32) 20.49 (20.70, 20.27)
Change Hb (g/dl) day 0–day 14
c 0.12 (20.04, 0.27) 20.05 (20.23, 0.13) 0.11 (20.02, 0.24) 20.34 (20.85, 0.17) 20.27 (20.52, 20.03) 20.22 (20.51, 0.06)
Change Hb (g/dl) day 0–day 28
c 0.05 (20.10, 0.20) 20.17 (20.35, 0.01) 20.03 (20.16, 0.10) 20.26 (20.61, 0.09) 20.31 (20.53, 20.09) 20.13 (20.45, 0.18)
Values are hazard ratio (95% CI) or OR (95% CI), as indicated.
aHazard ratio of treatment (first listed) versus control.
bAnalysis based on zero-inflated Poisson models reported as the OR of excess gametocytes during follow-up, and the ratio of gametocyte carriage days (for those with
gametocytes).
cMean change (difference) between day 0 and day of follow-up.
doi:10.1371/journal.pmed.1001119.t004
Figure 4. Treatment efficacy by pair-wise comparison and by site. Risk difference and 95% CI for three pair-wise analyses by site for PCR-
unadjusted (left panel) and -adjusted (right panel) ACPR at days 28 (filled circles) and 63 (open circles) (ITT population) (A) ASAQ versus DHAPQ; (B) AL
versus ASAQ; (C) AL versus DHAPQ. BF, Burkina Faso; GA, Gabon; MZ, Mozambique; NG, Nigeria; RW, Rwanda; UG, Uganda; ZM, Zimbabwe.
doi:10.1371/journal.pmed.1001119.g004
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length and efficacy of the post-treatment prophylaxis may also be
influenced by the transmission intensity. In Tororo (Uganda), a
site with very high entomological inoculation rates (.500 infective
bites/person/year) [34], the difference in the cumulative risk of
recurrent malaria between AL and DHAPQ decreased when the
follow-up period was extended to 63 d, suggesting that piper-
aquine’s long elimination half-life could do little against the
overwhelming risk of recurrent malaria [35]. Nevertheless, in our
study and at the same site, the risk of recurrent infections at day
Figure 6. Hematological recovery by treatment and day of follow-up. Hematological recovery determined by Hb changes compared to day
0. The boxplots contain the following information: median (bold line), first and third quartile (box), whiskers extending to 1.56interquartile range,
and all more extreme values.
doi:10.1371/journal.pmed.1001119.g006
Figure 5. Gametocyte prevalence by treatment and day of follow-up. (A) All patients regardless of gametocytemia at enrollment; (B) patients
with gametocytes at enrollment excluded.
doi:10.1371/journal.pmed.1001119.g005
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the AL arm. When considering the forest plot comparing AL
and DHAPQ, the OR tended to be lower at sites with the
highest transmission intensity, suggesting that piperaquine’s longer
post-treatment prophylaxis still had an effect despite the high
transmission. It should also be noted that places with an intensity
of transmission as high as or higher than that of Tororo are not
common, particularly in the current context of decreasing malaria
Table 6. Biochemistry tests for liver and renal function before and after treatment.
Test Treatment Group
ASAQ DHAPQ AL CD+A
ALAT with clinically significant values above normal range (n/N)
Day 0 1.8 (17/930) 0.7 (10/1403) 1.4 (16/1165) 1.5 (6/406)
Day 7 1.1 (9/808) 0.2 (3/1315) 0.4 (4/1077) 0.0 (0/395)
Day 28 1.0 (7/713) 0.3 (4/1248) 0.1 (1/913) 0.0 (0/290)
ALAT, median (IQR)
Day 0 23.0 (16.0–33.0) 23.3 (17.0–33.0) 23.8 (16.4–33.3) 25.0 (19.1–36.4)
Day 7 22.0 (15.4–31.0) 22.3 (16.6–30.2) 23.0 (16.9–31.1) 23.0 (17.9–33.9)
Day 28 21.0 (15.0–29.0) 22.0 (16.4–30.0) 23.0 (16.2–31.0) 23.0 (18.0–30.7)
Creatinine with clinically significant values above normal range (n/N)
Day 0 0.2 (2/903) 0.1 (2/1372) 0.0 (0/1165) 0.0 (0/406)
Day 7 0.1 (1/782) 0.0 (0/1292) 0.0 (0/1072) 0.0 (0/401)
Day 28 0.0 (0/680) 0.0 (0/1199) 0.2 (2/909) 0.7 (2/293)
Creatinine, median (IQR)
Day 0 38.0 (31.4–44.2) 44.2 (34.0–58.3) 45.1 (35.4–62.0) 40.0 (31.0–60.0)
Day 7 37.1 (31.0–44.2) 44.2 (34.3–60.1) 45.1 (36.0–60.1) 38.0 (26.5–53.0)
Day 28 38.0 (30.3–44.2) 44.2 (34.3–60.1) 49.5 (40.8–62.8) 41.5 (31.0–61.0)
Liver function: alanine aminotransferase (ALAT; IU/l); renal function: creatinine (mmol/l). Sample size indicated in the denominator of proportions of values above the
normal range.
IQR, interquartile range.
doi:10.1371/journal.pmed.1001119.t006
Table 5. Summary of adverse events up to day 28 (for patients having received at least one dose).
Safety Population ASAQ (n=1,003) DHAPQ (n=1,468) AL (n=1,225) CD+A( n=412)
At least one AE 669 (66.7) 963 (65.6) 758 (61.9) 314 (76.2)
Most common AEs
a
Anemia 143 (14.3) 141 (9.6) 38 (3.1) 71 (17.2)
Diarrhea 112 (11.2) 166 (11.3) 142 (11.6) 40 (9.7)
Vomiting 106 (10.6) 123 (8.4) 102 (8.3) 52 (12.6)
Pyrexia 215 (21.4) 371 (25.2) 339 (27.7) 173 (42.0)
Hb decreased 40 (4.0) 103 (7.0) 83 (6.8) 70 (17.0)
Anorexia 94 (9.4) 130 (8.9) 121 (9.9) 55 (13.3)
Cough 314 (31.3) 470 (32.0) 387 (31.6) 155 (37.6)
At least one related AE 233 (23.2) 291 (19.8) 200 (16.3) 101 (24.5)
Most common related AEs
a
Anemia 98 (9.8) 96 (6.5) 31 (2.5) 61 (14.8)
Vomiting 59 (5.9) 49 (3.3) 36 (2.9) 15 (3.6)
SAE 15 (1.5) 10 (0.7) 6 (0.5) 6 (1.5)
Related SAE
b 4 (0.4) 4 (0.3) 2 (0.2) 2 (0.5)
At least one AE that caused discontinuation 2 (0.2) 2 (0.1) 1 (0.1) 1 (0.2)
At least one SAE that caused death 1 (0.1) 1 (0.1) 2 (0.2) 1 (0.2)
Values are n (percent).
aAEs and related AEs recorded in, respectively, at least 10% and 5% of patients in any treatment group.
bA related SAE is a SAE that the investigator classified as possibly, probably, or definitely related to the study drug.
doi:10.1371/journal.pmed.1001119.t005
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occurrence of a second clinical attack, via a long post-treatment
prophylactic effect, represents an advantage at the individual level,
the increased risk of selecting resistant parasites among the new
infections should be considered. Such risk occurs during a specific
period, the ‘‘window of selection,’’ whose opening and duration is
proportional to the drug terminal elimination half-life [36].
Therefore, according to this model, such window would be
shorter for lumefantrine (3–5 wk) than for piperaquine. Though
this should not be a deterrent for the large-scale deployment of
DHAPQ, setting up a reliable early warning system for the
detection of resistance, possibly by both in vivo and in vitro tests,
would be essential.
In children treated with AL, gametocyte prevalence during
follow-up and gametocyte carriage time were significantly lower
than in children treated with either DHAPQ or ASAQ. The
difference remained significant for gametocyte carriage time even
when excluding patients with gametocytes at enrollment. Higher
gametocyte carriage after treatment with DHAPQ, when
compared to either AL or mefloquine-artesunate, has already
been reported in some [14,35,37–39] but not all trials [40].
Similarly, gametocyte carriage was higher after treatment with
ASAQ than with AL in some [29,41] but not all studies [27]. The
meaning of such differences in terms of transmission potential is
unclear. Compared to molecular methods, microscopy detects
only a small fraction of gametocyte carriers, both in individuals
with asymptomatic infections [42] and in patients treated with an
antimalarial [39]. Children with microscopically detectable
gametocytes are more likely to be infectious but those with sub-
microscopic gametocytes can also transmit, albeit less efficiently
[42]. The gametocyte prevalence as determined by molecular
methods has been observed to be higher in patients treated with
DHAPQ than with AL [39]. However, about 60% of children
treated with AL and without microscopically detectable gameto-
cytes were infectious to mosquitoes, with little difference between
treatments, though the probability of a mosquito becoming
infected was significantly lower for the ACT (AL and sulfadox-
ine-pyrimetamine-artesunate) than for monotherapy or non-ACT
combinations [43]. This indicates the difficulty of determining the
transmission potential on the basis of the gametocyte carriage time
as determined by microscopy, so that the differences in gametocyte
carriage observed in our trial may not necessarily relate to a
significantly different transmission potential. Considering that
ACTs reduce the production of gametocytes by both decreasing
the asexual reservoir and destroying a substantial proportion of
immature, developing gametocytes, still sequestered in the
microvasculature [44], and that parasite clearance was similar in
the four study arms, the difference observed between the three
ACTs may relate to their ability to clear almost mature forms not
released in the blood stream yet.
Hematological recovery up to day 28 post-treatment was similar
for all ACTs tested except for CD+A, for which this was
significantly slower, with a more marked Hb decrease up to day
7, confirming previous results [25]. In addition, in the CD+A
group, anemia was diagnosed more frequently as AE, providing
additional evidence for the higher risk of anemia for this
treatment. Aside from anemia risk related to CD+A, all regimens
were well tolerated.
In conclusion, this is, to our knowledge, the largest head-to-head
comparison of most of the currently available ACTs for falciparum
malaria in sub-Saharan Africa. CD+A was suspended partway
through the trial, leaving AL, ASAQ, and DHAPQ under
investigation. These three ACTs showed excellent efficacy, up to
day 63 post-treatment, but the risk of recurrent infections was
significantly lower, even in areas of high transmission, for DHAPQ,
followed byASAQ, and then AL.Although the gametocyte carriage
rate differed between regimens, with those treated with AL having
the lowest carriage rate and those treated with ASAQ having the
highest carriage rate, the meaning of these different carriage rates
with relation to transmission potential is unclear. The possibility of
adding a single dose of primaquine to any of these three ACTs, with
the objective of further reducing gametocyte carriage, should be
explored [41,45]. AL and/or ASAQ are already included in the
antimalarial drug policies of many sub-Saharan African countries.
This study confirms that DHAPQ is a valid third option for the
treatment of uncomplicated P. falciparum malaria, as its efficacy is
excellent and comparable to the other ACTs, while its long post-
treatment prophylaxis could be an additional advantage.
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Background. Malaria is a global public-health problem. Half
the world’s population is at risk of this mosquito-borne
parasitic disease, which kills a million people (mainly children
living in sub-Saharan Africa) every year. Although several
parasites cause malaria, Plasmodium falciparum is
responsible for most of these deaths. During the second
half of the 20th century, the main treatments for malaria
were inexpensive ‘‘monotherapies’’ such as chloroquine and
sulfadoxine-pyrimethamine. Unfortunately, the malaria
parasite quickly developed resistance to many of these
monotherapies, and in the 1990 s, there was a widespread
upsurge in P. falciparum malaria. To combat this increase, the
World Health Organization (WHO) now recommends
artemisinin-based combination therapy (ACT) for first-line
treatment of P. falciparum malaria in all regions where there
is drug-resistant malaria. In ACT, artemisinin derivatives (new,
fast-acting antimalarial drugs) are used in combination with
another antimalarial drug (a partner drug) to reduce the
chances of P. falciparum becoming resistant to either drug.
Why Was This Study Done? WHO currently recommends
five ACTs—amodiaquine-artesunate (ASAQ), dihydroartemisinin-
piperaquine (DHAPQ), artemether-lumefantrine (AL), artesunate-
mefloquine, and artesunate-sulfadoxine-pyrimethamine—for
the treatment of malaria. Its treatment guidelines state that
the choice of ACT in a country or region should be based on the
local level of resistance to the non-artemisinin-based partner
drug in the combination. However, data on resistance levels to
these partner drugs are scarce or unavailable for many sub-
Saharan African countries. To help these countries make an
informed choice about their national antimalarial treatment
policies, in this randomized, non-inferiority trial, the researchers
compare the efficacy and safety off o u rA C T si nA f r i c a nc h i l d r e n
with uncomplicated (mild) P. falciparum malaria. In a randomized
trial, groups of randomly chosen patients with a specific disease
are given different treatments and then followed to compare the
outcomes of these interventions. A non-inferiority trial
investigates whether one treatment is not worse than another
treatment.
What Did the Researchers Do and Find? Each of twelve
sites in seven sub-Saharan African countries compared three
ACTs out of ASAQ, DHAPQ, AL, and chlorproguanil-dapsone-
artesunate (CD+A). Overall, 4,116 young children with
uncomplicated malaria were treated with ACT, actively
followed up for 28 days (their parents brought them back
to the site for pre-arranged check-ups), and passively
followed up for six months (parents brought their children
back if they developed any illnesses). At each visit, blood
samples were examined for the presence of parasites, and a
technique called PCR was used to determine which cases of
malaria were new infections and which were recurrences of
the original infection. The researchers then calculated the
percentage of patients with no infection or with a new
infection (the PCR-adjusted adequate clinical and
parasitological response [ACPR]) and the percentage of
patients with no infection (the PCR-unadjusted ACPR). For
the PCR-adjusted efficacy, three pair-wise comparisons
(DHAPQ versus AL, DHAPQ versus ASAQ, and ASAQ versus
AL) showed non-inferiority at 28 days. That is, for example,
similar percentages of patients given DHAPQ or AL (97.3%
and 95.5%, respectively) had either no infection or a new
infection. CD+A was less efficacious than the other three
treatments. For the PCR-unadjusted efficacy, AL was
significantly less efficacious than DHAPQ and ASAQ;
DHAPQ had a higher efficacy than ASAQ, but non-
inferiority could not be excluded. That is, the difference in
efficacy of these two drugs might have happened by chance.
What Do These Findings Mean? These findings suggest
thatAL, ASAQ,andDHAPQareall efficacious for thetreatment
of uncomplicated malaria in children; CD+A was withdrawn
partway through the trial because of side effects, but these
findings also suggestthatit waslessefficacious than the other
ACTs. Importantly, the PCR-unadjusted results indicate that
the risk of children becoming re-infected with malaria
parasites soon after treatment was lowest for DHAPQ,
followed by ASAQ, and then AL. Because these findings are
based on pooled results from seven sub-Saharan African
countries, they are likely to be generalizable and thus of use in
setting national antimalarial drug policies throughout the
region. AL and ASAQ are already included in the antimalarial
drug policies of many sub-Saharan African countries, note the
researchers, but these findings support the WHO
recommendation that DHAPQ should also be considered for
the treatment for uncomplicated P. falciparum malaria.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001119.
N Information is available from WHO on malaria (in several
languages); the 2010 World Malaria Report provides details
of the current global malaria situation; the WHO Guidelines
for the Treatment of Malaria and the report Assessment
and Monitoring of Antimalarial Drug Efficacy for the
Treatment of Uncomplicated Malaria are available
N The US Centers for Disease Control and Prevention provide
information on malaria (in English and Spanish), including
a selection of personal stories about malaria
N Information is available from the Roll Back Malaria
Partnership on the global control of malaria including fact
sheets about ACTs and about malaria in Africa
N MedlinePlus provides links to additional information on
malaria (in English and Spanish)
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